Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 4/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31298682 | 0.96 | PTPN1 (0.41) | PTPN1TLR2TLR1CA1CA2 | |
| SCHEMBL29521884 | 0.93 | TLR2 (0.41) | TLR2TLR1CA1CA2CXCR3 | |
| SCHEMBL31298690 | 0.91 | PTPN1 (0.46) | PTPN1TLR2TLR1CA1CA2 | |
| SCHEMBL20530037 | 0.89 | ALB (0.47) | TLR2 | |
| SCHEMBL30783464 | 0.89 | PTPN1 (0.43) | PTPN1TLR2TLR1GRB2PAX8 | |
| SCHEMBL31298675 | 0.89 | ALB (0.47) | TLR2 | |
| SCHEMBL30783463 | 0.89 | PTPN1 (0.43) | PTPN1TLR2TLR1GRB2PAX8 | |
| SCHEMBL29521888 | 0.87 | ALB (0.44) | TLR2TLR1 | |
| SCHEMBL31298693 | 0.87 | ALB (0.48) | TLR2TLR1 | |
| SCHEMBL30895538 | 0.87 | TLR2 (0.49) | TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | CCR6, OGFRL1, IL6ST | PTPN1 1228/4885TLR2 311/4885TLR1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.